Earnings call transcript: Ceragon Networks Q1 2026 revenue beats estimates

Ceragon Networks reported Q1 2026 revenue of $85 million, topping the $80.36 million consensus by 5.77%, while EPS met expectations at $0.01. Gross margin improved to 36.0% from 33.5% a year ago, but EPS fell 73% year over year and management flagged Q2 gross-margin pressure from a North America supply-chain delay, FX headwinds, and higher industry costs. The company reaffirmed full-year 2026 revenue guidance of $355 million-$385 million and said India, EMEA, and new product demand remain strong, helping shares rise 6.77% premarket.

Analysis

CRNT’s setup is less about one-quarter beats and more about a changing revenue mix that can create a misleading read-through on the P&L. India and private-network wins appear to be validating the product roadmap, but the real second-order effect is that Ceragon is becoming more exposed to deployment-heavy, mix-sensitive revenue while still depending on a few large carrier rollouts to stabilize margins. That means the stock can continue to rerate on bookings momentum even if near-term earnings quality looks choppy.

The key catalyst is the North America timing slip, which looks temporary but compresses gross margin right when operating leverage should have been improving. If management executes the promised catch-up in Q3, the market may reward the stock twice: first for revenue visibility, then for margin normalization. If not, the current enthusiasm around “de-risked” guidance can unwind quickly because the market is implicitly discounting a smooth H2 ramp that is now carrying execution risk.

The more interesting contrarian angle is that competitive dislocation is not automatically a secular share gain; it may simply pull forward orders and lengthen deal cycles as customers wait for vendor decisions. Still, Ceragon is one of the few names in the sub-$300M revenue band with both a credible growth narrative and tangible operating cash generation, which makes it unusually sensitive to incremental evidence on Europe and the new FR2 platform. The market likely underestimates how much a single successful North American design win could matter for 2027 outside of the core India business.

Key Decisions for Investors

• Long CRNT into any post-earnings pullback over the next 1-2 weeks; use the mix-driven Q2 margin weakness as the entry window, with a target tied to Q3 evidence of North America catch-up and a stop if channel checks imply the component issue is still unresolved by mid-summer.
• Buy CRNT call spreads for Sep/Oct 2026 expiration; the asymmetry is attractive if Q3 revenue and margin rebound validate management’s bridge, while downside is partially cushioned by already-cleared demand visibility in India.
• Pair trade: long CRNT / short NOK over the next 3-6 months; CRNT is the cleaner beneficiary of customer displacement and product-cycle momentum, while NOK carries more execution risk from restructuring/disposal uncertainty.
• If you want lower beta exposure, express the thesis via a long CRNT vs short a broader telecom-equipment basket; CRNT’s idiosyncratic booking catalysts are stronger, but the risk is that macro capex weakness hits all names simultaneously.
• Trim or hedge CRNT if Q2 orders are strong but gross margin does not stabilize sequentially by Q3; that would signal the mix story is becoming a permanent margin ceiling rather than a transitory bridge.